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parkinsonian syndromes can be induced by exposure
to rotenone, which causes highly selective nigrostriatal
dopaminergic degeneration, even though it inhibits mi-
tochondrial complex I activity across all brain subre-
gions (Betarbet et al., 2000). The discovery of autoso-
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mal-recessively inherited mutations in the parkin (KitadaBoston, Massachusetts 02115
et al., 1998), DJ-1 (Bonifati et al., 2003), and PINK1 (Va-2 Laboratory of Neurogenetics
lente et al., 2004) genes associated with familial parkin-National Institute on Aging
sonism demonstrated that the loss of function of a singleNational Institutes of Health
gene product can lead to nigral degeneration and theBethesda, Maryland 20892
clinical manifestations of parkinsonism (Table 1). This
infers that these gene products are essential for the
survival of human nigral neurons (although autopsyRecessively inherited mutations in parkin, DJ-1, and
studies for DJ-1 and PINK1 cases are not yet available).PINK1 have recently been linked to familial forms of
Identification of the cellular and physiological functionsparkinsonism. These syndromes are often clinically
of these gene products, therefore, would be invaluableindistinguishable from Parkinson’s disease, as similar
for the elucidation of the pathogenic mechanisms under-neuronal groups, notably dopaminergic neurons, are
lying the selective degeneration of dopaminergic neu-selectively affected. Studies of the functions of these
rons. In this review, we will outline emerging experimen-gene products may provide insights into the patho-
tal evidence and our developing concepts about thegenic mechanisms underlying the selective degenera-
function and dysfunction of parkin, DJ-1, and PINK1.tion of dopaminergic neurons. Emerging evidence that
One surprising outcome of these analyses is the possi-one or several of these genes play important roles in
ble convergence of these genes in the following essen-mitochondrial function and the dopaminergic system
tial cellular functions.suggests that these events may be early steps of the
Ubiquitin Proteasome Systempathophysiological changes of the disease. This re-
Following the identification of parkin mutations, severalview will summarize recent advances in our under-
groups reported that parkin is an E3 ubiquitin-proteinstanding of these gene products, with emphasis on
ligase. The addition of chains of ubiquitin to target pro-the surprising convergence of their functions.
teins by E3 ligases regulates the rate of entry of proteins
to the proteasome. Hence, E3 ligases act as gatekeepersThe primary neuropathological hallmarks of Parkinson’s
for degradation of proteasome substrates. The domaindisease (PD) are progressive degeneration of various
structure of parkin is similar to other E3 ligases, with twoneuronal groups and the presence of intraneuronal cyto-
C-terminal really interesting new gene (RING) domainsplasmic inclusions known as Lewy bodies (LBs). Many
separated by an in-between-ring (IBR) domain. The E2of the clinical manifestations of PD are a consequence
enzymes UbCH7 or UbCH8, which carry activated ubi-of the loss of dopaminergic neurons in the substantia
quitin, bind to this RING-IBR-RING motif. Most sub-nigra pars compacta (SNpc). These neurons give rise to
strates (see below) also bind to the RING-IBR-RING re-the nigrostriatal pathway, and as a consequence of their
gion, often to RING1. By analogy to other E3 ligases
loss, there is depletion of dopamine (DA) in the striatum,
with similar domain structures, it is likely that substrates
where DA is required for normal motor function. This
are ubiquitylated by binding to RING1 in close proximity
depletion therefore causes a spectrum of movement to the E2-ubiquitin and the ubiquitin is then transferred
disorders, such as the clinical triad of resting tremor, to a substrate lysine residue. The structural basis of
rigidity, and bradykinesia. Neurodegeneration in PD, substrate recognition by parkin has not yet been eluci-
however, is not limited to the SNpc, as it also occurs in dated and is a major unanswered question in the field. At
other brain subregions, including noradrenergic neurons the N-terminal region of parkin is a ubiquitin-like domain
in the locus ceruleus and serotonergic neurons in the that interacts directly with the proteasome cap protein
dorsal raphe nucleus. The occurrence of PD is largely Rpn10 (Sakata et al., 2003). Hence, the most likely func-
sporadic, but clinical syndromes mimicking sporadic PD tion of parkin is to promote polyubiquitylation and trans-
occur with an autosomal-recessive pattern of inheri- fer to the proteasome. It should be acknowledged, how-
tance in a number of families, which represent a small ever, that many cellular processes employ ubiquitylation
percentage of all PD cases. and related modifications to control protein activity
Although degeneration of the nigrostriatal pathway rather than degradation. For example, there is increasing
accounts for many of the clinical manifestations of PD, evidence that ubiquitylation (especially monoubiquityla-
the underlying mechanisms that provoke neuronal cell tion) affects intracellular targeting of proteins rather than
loss remain unclear. Much attention has been devoted degradation. This leads to effects of the ubiquitin protea-
to the apparent selective vulnerability of nigral neurons. some system (UPS) on synaptic function, receptor inter-
For example, it has been known for several years that nalization, and other cellular processes, such as tran-
scriptional regulation (Marx, 2002). Whether parkin has
effects on some of these other processes has not*Correspondence: jshen@rics.bwh.harvard.edu (J.S.); cookson@
mail.nih.gov (M.R.C) been addressed.
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Table 1. Recessively Inherited Mutations Linked to Familial Parkinsonism
Gene Locus Inheritance # of Mutations Type of Mutations Putative Function
parkin (PARK2) 6q25-27 AR 40 exonic deletion and duplication; E3 ubiquitin ligase
nonsense; frame-shift; missense
DJ-1 (PARK7) 1p36 AR 2 exonic deletion (exons 1-5); missense oncogene??? antioxidant?
(L166P)
PINK1 (PARK6) 1p35-36 AR 2 nonsense (W437Stop); missense (G309D) kinase?
Parkin appears to conjugate ubiquitin to multiple sub- volved in the protection of oxidative stress were found
in the ventral midbrain of parkin knockout mice (Palacinostrate proteins, at least in vitro, some of which may be
toxic if allowed to accumulate. For example, the septin et al., 2004). These alterations were accompanied by
decreases in mitochondrial respiratory capacity andCDC-rel1 has been shown to be toxic in rats when over-
expressed using viral vectors in vivo. Parkin suppresses age-dependent increases of oxidative damage. Second,
mitochondrial pathology is a prominent feature in thethe toxicity of another substrate, Pael receptor 1 (Yang
et al., 2003), and similar relationships may hold for other flight muscle of Drosophila parkin null mutants (Greene
et al., 2003; Pesah et al., 2004). This mitochondrial dam-substrates. Whether parkin regulates the degradation
of these proteins in vivo is difficult to address, although age may be responsible for the observed apoptosis in
the flight muscle, which is a heavily energy-dependentit is important to note that analysis of parkin null mice
did not identify altered steady-state levels of CDC-rel1 tissue in insects. Third, overexpression of parkin in vitro
decreases cellular sensitivity to agents (e.g., ceramide)and other substrates (Goldberg et al., 2003). Parkin also
protects against the deleterious effects of overexpres- that trigger mitochondria-dependent apoptosis (Darios
et al., 2003). The fact that loss of parkin function insion of mutant -synuclein in some models (Petrucelli
et al., 2002; Yang et al., 2003). Overall, it appears that mice causes mitochondrial dysfunction and oxidative
damage in the absence of neuronal degeneration seemsparkin’s E3 ligase activity is required for protection of
cell survival, as pathogenic inactivating mutations do to lend support for a causal role of mitochondrial dys-
function in nigral degeneration. Of course, this notionnot protect cells.
These observations support two concepts. First, most will have to be confirmed in a model system that exhibits
mitochondrial dysfunction and eventually develops sub-evidence to date suggests that parkin can function as
E3 ubiquitin ligase, although these studies tend to be stantial degeneration of nigral neurons.
How and whether parkin regulates mitochondrial func-done in vitro or using overexpressing cell lines. Thus, it
is logical to predict that parkin regulates the steady- tion through its E3 ligase activity is not yet clear. None
of the mitochondrial proteins were found to accumulatestate levels of substrate proteins, thereby limiting the
abundance of damaged and/or damaging proteins. The in the absence of parkin, suggesting that parkin does not
regulate their abundance directly through its E3 ligasephysiological substrates of parkin, however, remain un-
clear. Second, parkin is neuroprotective against a num- activity (Palacino et al., 2004). In addition, none of the
substrates identified for parkin’s E3 ligase activity haveber of stresses, including but not limited to overexpres-
sion of mutant-synuclein. This is consistent with parkin been implicated in mitochondrial function. However, it
remains possible that physiological substrates of par-acting downstream of cellular stress triggers. The key
questions remain: what are the downstream targets of kin’s E3 ligase activity, which are yet to be identified,
may be involved in the biogenesis of these mitochondrialparkin, through which parkin mediates its protection of
nigral neurons; and is there any evidence linking parkin proteins. Interestingly, a small proportion of parkin is
associated with the outer mitochondrial membrane, atto other recessive parkinsonian genes, or does each
impinge on distinct pathways? least in cultured cells (Darios et al., 2003), though parkin
lacks an obvious mitochondrial targeting sequence. ItMitochondrial Dysfunction and Oxidative Stress
The idea that mitochondrial dysfunction may play a key has been reported that inhibition of proteasome function
decreases mitochondrial protein synthesis and activityrole in PD pathogenesis has been around for a long time,
since postmortem studies have shown mitochondrial and increases the production of reactive oxygen species
(Sullivan et al., 2004). Therefore, it is also possible thatimpairment and oxidative damage in PD brains (Beal,
2003; Jenner and Olanow, 1998). This is further sup- the observed changes in mitochondrial protein expres-
sion are a downstream effect of parkin on net protea-ported by observations that mitochondrial complex I
inhibitors, such as MPTP, rotenone, and paraquat, can some function.
Given the evidence mentioned above, several labora-be used to produce a parkinsonian syndrome in experi-
mental models and humans (Dauer and Przedborski, tories have evaluated whether the more recently identi-
fied DJ-1 and PINK1 affect mitochondrial function and/2003). The coexistence of mitochondrial dysfunction
and nigral cell loss in these systems makes it difficult or oxidative stress. Although initial evidence suggested
that wild-type and mutant DJ-1 localized differentiallyto establish whether mitochondrial dysfunction is causal
or a secondary consequence of nigral degeneration. to mitochondria in transfected cells (Bonifati et al., 2003),
a more recent report suggests that oxidizing conditionsInterestingly, recent studies have surprisingly indicated
a role for parkin in mitochondrial function. First, using favor DJ-1 localization to the outer mitochondrial mem-
brane (Canet-Aviles et al., 2004). It is important to notean unbiased proteomics approach, alterations in the
apparent abundance of several mitochondrial proteins that this observation has not yet been confirmed in vivo
at physiological expression levels and the mechanisticin the electron transport chain and several proteins in-
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Table 2. Parkin-Deficient Models
References Phenotypes
Mouse 1 nigrostriatal dysfunction (e.g., increased striatal extracellular dopamine, reduced synaptic
excitability of striatal spiny neurons, behavioral impairments) but absence of
dopaminergic neuron loss
2 behavioral deficits, inhibition of glutamate neurotransmission, increased dopamine, increased
GSH levels, absence of dopaminergic neuron loss
3 impaired mitochondrial function, alterations in mitochondrial proteins and proteins involved
in protection of oxidative stress, age-dependent increases in oxidative damage
Drosophila 4 reduced lifespan, apoptotic muscle degeneration and male sterility associated with
mitochondrial pathology, absence of dopaminergic neuron loss
5 male and female sterility, shorter lifespan by paraquat treatment, muscle
degeneration, absence of dopaminergic neuron loss
The quaking mouse, which contains a large genomic deletion encompassing both the parkin gene and the adjacent parkin co-regulated
gene, also exhibits intact dopaminergic neurons in the substantia nigra (Lorenzetti et al. 2004). 1, Goldberg et al., 2003; 2, Itier
et al., 2003; 3, Palacino et al., 2004; 4, Greene et al., 2003; 5, Pesah et al., 2004.
basis for DJ-1 localization to mitochondria has not been on dopaminergic neurons (Hoglinger et al., 2003). It is
possible that both pathways are affected to induce neu-elucidated. Importantly, DJ-1 overexpression protects
against mitochondrial damage (Canet-Aviles et al., ronal death in recessive parkinsonism, and selective
vulnerability results from a complex interplay between2004), and knockdown models show heightened sensi-
tivity to oxidative stress (Yokota et al., 2003). Very re- the two stresses. In this context, it is worth noting that
several recent studies implicate another old suspect forcently, the first report on the linkage of PINK1 mutations
to familial parkinsonism shows that PINK1 contains a dopaminergic cell loss in parkinsonism: dopamine itself.
Dopaminergic Systemmitochondrial localization sequence and is indeed local-
ized to mitochondria (Valente et al., 2004). PINK1 also As stated above, a key feature of parkinsonian disorders
is the selective loss of dopaminergic neurons in theprotects cells against loss of mitochondrial membrane
potential triggered by application of proteasome inhibi- SNpc, resulting in reduced dopamine input to the stria-
tum. Postmortem analysis of parkin mutation-bearingtors. Overall, it is still very early for the studies of DJ-1
and PINK1. For example, how and whether these pro- patients confirmed the selective loss of DA neurons in
the SNpc, though neuropathological studies of patientsteins regulate mitochondrial function is unknown, and
the substrates for the presumed PINK1 kinase activity carrying mutations in DJ-1 and PINK1 are still lacking.
Inactivation of parkin function in mice and flies, however,are not yet identified. Given that PINK1 has a mitochon-
drial targeting sequence, it is reasonable to expect that fails to reproduce the selective loss of dopaminergic
neurons seen in human patients (Goldberg et al., 2003;its physiological substrates may include mitochondrial
proteins. It should be emphasized that knockout models Greene et al., 2003; Itier et al., 2003) (Table 2). The same
preservation of nigral cells is seen in the quaking mousefor DJ-1 or PINK1 have not yet been reported. In one
knockdown model for DJ-1, increased sensitivity of cells strain, which harbors deletions of both the parkin and
parkin co-regulated genes (Lorenzetti et al., 2004).to a number of stresses was noted, but mitochondrial
function was not examined (Yokota et al., 2003). Results These observations suggest that frank dopaminergic
cell death may occur over a more protracted time scalefrom such experiments are eagerly awaited, especially
using relevant in vivo systems. than that available in experimental animals or that an
additional pathogenic event(s) may be necessary to pro-Thus, it seems that the triad of genes responsible for
recessive parkinsonism are all variably associated with duce such cell death. These models are nevertheless
valuable for the identification of the early changes inmitochondria and protect against some combination of
mitochondrial dysfunction and/or oxidative stress. More dopaminergic neuronal physiology that may promote or
eventually precipitate selective nigral degeneration. Atbroadly, selective vulnerability of nigral neurons in par-
kinsonism is likely to be multifaceted and may involve the same time, such analyses will shed light on the
normal function of parkin and its role in dopaminergiceither mitochondrial or proteasomal pathways or both.
Although beyond the scope of the present minireview, neuronal survival.
Recent analysis of parkin null mice has indeed re-it is also of interest that the known dominant mutation
associated with LB-positive PD, -synuclein, has been vealed disturbances in dopaminergic physiology. Using
in vivo microdialysis, extracellular concentrations of do-linked to both proteasomal dysfunction (Petrucelli et al.,
2002, and references therein) and mitochondrial damage pamine were found to be increased in the striatum,
though striatal levels of DA and its metabolites DOPAC(Dauer and Przedborski, 2003; Dawson and Dawson,
2003). DJ-1 (Yokota et al., 2003) and PINK1 (Valente et and HVA were unaffected (Goldberg et al., 2003). This
effect appears to be specific for dopamine, as levels ofal., 2004) have both been suggested to protect cells
against proteasome dysfunction, although, as neither other neurotransmitters, such as serotonin and nor-
adrenaline, are not altered in the absence of parkin (Itiergene has an apparent direct link to the UPS, it is unclear
how either DJ-1 or PINK1 is protective against these et al., 2003). However, the precise mechanism by which
loss of parkin leads to the increase in extracellular DAstresses. There is evidence that inhibitors of the protea-
some and mitochondrial complex I have additive effects is less clear. Additional deficits in the dopaminergic sys-
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tem in parkin null mice include reduced synaptic re- of these genes, we hope to understand the complex
sponses in the striatal spiny neurons and behavioral relationships between idiopathic PD and the recessive
impairment in paradigms that are sensitive to the nigro- parkinsonian syndromes and eventually to develop
striatal pathway (Goldberg et al., 2003). Interestingly, a novel ways in which to protect nigral neurons from the
proportion of parkin protein localizes to the postsynaptic disease process.
density via an interaction with CASK/lin-1, and at least
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